Vertex Pharma (VRTX) Tops Q2 EPS by 3c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Vertex Reports Second Quarter 2016 Financial Results
July 27, 2016 4:01 PM EDT-Second quarter 2016 cystic fibrosis product revenues of $426 million; $245 million for ORKAMBI® (lumacaftor/ivacaftor) and $180 million for KALYDECO® (ivacaftor)-
-Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705 million-
-Pipeline of investigational CF medicines continues to progress and expand with addition of recent Moderna mRNA collaboration-
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2016 and reviewed recent progress with its approved and investigational cystic... More
